Stifel Nicolaus analyst Rick Wise reiterated a Buy rating on Edwards Lifesciences (EW) on January 31 and set a price target of $190. The company’s shares closed on Friday at $168.70, close to its 52-week high of $175.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 13.0% and a 68.9% success rate. Wise covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Obalon Therapeutics Inc, and Intuitive Surgical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $177.92 average price target, a 5.5% upside from current levels. In a report issued on January 18, Merrill Lynch also upgraded the stock to Buy with a $190 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $175 and a one-year low of $121.40. Currently, Edwards Lifesciences has an average volume of 1.38M.
Based on the recent corporate insider activity of 117 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Robert Sellers, the VP, Corp. Contr of EW sold 7,859 shares for a total of $1,203,631.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.
